Lv4
520 积分 2021-12-21 加入
Mitochondrial control of fuel switching via carnitine biosynthesis
1个月前
已完结
Non-alcoholic fatty liver disease
5个月前
已完结
YAP/TAZ as master regulators in liver regeneration and disease: insights into mechanisms and therapeutic targets
5个月前
已完结
Nonalcoholic fatty liver disease: lifestyle and quality of life
5个月前
已完结
Imbalance in ALR ubiquitination accelerates the progression of nonalcoholic steatohepatitis to hepatocellular carcinoma
5个月前
已完结
Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease
5个月前
已完结
Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes
5个月前
已完结
Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges
6个月前
已完结
Resmetirom: The First FDA-Approved Drug for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with a Perspective on Precision Medicine
6个月前
已完结
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
6个月前
已完结
皖公网安备34019202002308
